^
    Back
    Association details:
    Biomarker:IL13RA2 overexpression
    Cancer:Renal Cell Carcinoma
    Drug:sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    PLoS One
    Title:

    Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma

    Published date:
    06/26/2015
    Excerpt:
    ...the tumor growth of xenografts from IL13RA2-expressing 786-O cells was not suppressed by treatment with sunitinib...we showed that sunitinib-sensitive 786-O cells acquired resistance in vivo when IL13RA2 was overexpressed.
    DOI:
    10.1371/journal.pone.0130980